Takeda posts Phase 1 results for fazirsiran in subjects with hepatic impairment
Results were posted for a completed Phase 1 study testing fazirsiran pharmacokinetics across liver function levels.
Takeda had one notable update this week.
- Fazirsiran (TAK-999), Phase 1, hepatic impairment: Results were posted for a trial that examined how the body processes fazirsiran in people with mild, moderate, or severe liver problems compared with those with normal liver function.1 The study was non-randomized with a parallel design and enrolled 34 participants.1 All participants received a single fazirsiran injection and were followed for 6 months afterward.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.